"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
- Neuromuscular Effect
- Effect, Neuromuscular
- Neuromuscular Effects
- Effects, Neuromuscular
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".
This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.
Development of Objective Structured Assessment of Technical Skills in facial cosmetic procedures: Botulinum toxin neuromodulator and soft-tissue filler injection. J Am Acad Dermatol. 2022 02; 86(2):463-467.
Optical control of muscular nicotinic channels with azocuroniums, photoswitchable azobenzenes bearing two N-methyl-N-carbocyclic quaternary ammonium groups. Eur J Med Chem. 2020 Aug 15; 200:112403.
Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines. Dermatol Surg. 2020 05; 46(5):653-661.
Impact of Botulinum Toxin Type A Treatment of the Glabella and Crow's Feet on Static Forehead Rhytides. Dermatol Surg. 2019 01; 45(1):167-169.
Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con. J Urol. 2017 09; 198(3):500-501.
OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017 02; 197(2S):S216-S223.
A blinded randomized controlled trial to evaluate the use of botulinum toxin for pain control in breast reconstruction with tissue expanders. Ann Plast Surg. 2015 Mar; 74(3):281-3.
Consensus statement regarding storage and reuse of previously reconstituted neuromodulators. Dermatol Surg. 2015 Mar; 41(3):321-6.
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients. Dis Mon. 2013 Jul; 59(7):261-8.
RimabotulinumtoxinB versus OnabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study. Dermatology. 2013; 226(3):227-32.